Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA

Analytical and Bioanalytical Chemistry

Volumn 408, Issue 27, 2016, Pages 7669-7677

  Abd Elhadi, Suaad ^a   Basora, Misericordia ^b   Vilas, Dolores ^c   Tolosa, Eduardo ^c   Sharon, Ronit ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biomarkers; ELISA; Parkinson s disease; Phospholipids; Synuclein

Indexed keywords

AMINO ACIDS; BINS; BIOMARKERS; BLOOD; BODY FLUIDS; CELLS; CEREBROSPINAL FLUID; ENZYME INHIBITION; LIPIDS; PHOSPHOLIPIDS; PROTEINS;

BIOCHEMICAL PROPERTIES; CEREBRO SPINAL FLUIDS; CONVENTIONAL METHODS; ELISA; PHOSPHATIDYLETHANOLAMINE; POST-TRANSLATIONAL MODIFICATIONS; PROTEIN STRUCTURES; SYNUCLEIN;

ANTIBODIES;

ALPHA SYNUCLEIN; ANTIBODY; GANGLIOSIDE GM1; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PROTEIN BINDING;

ADULT; BLOOD; BLOOD CELL; CEREBROSPINAL FLUID; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PARKINSON DISEASE; PROCEDURES; PROTEIN CONFORMATION; PROTEIN FOLDING; SALIVA;

ADULT; ALPHA-SYNUCLEIN; ANTIBODIES; BLOOD CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; G(M1) GANGLIOSIDE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PHOSPHATIDYLETHANOLAMINES; PHOSPHATIDYLINOSITOLS; PHOSPHATIDYLSERINES; PHOSPHOLIPIDS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; SALIVA;

EID: 84991094065     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-016-9863-7     Document Type: Article

References (46)

1. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13–24.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211.
3. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121–34.
4. Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease-the gut-brain axis and environmental factors. Nat Rev Neurol. 2015;11(11):625–36.
5. Olanow CW, Wakeman DR, Kordower JH. Peripheral alpha-synuclein and Parkinson's disease. Mov Disord. 2014;29(8):963–6.
6. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003;17(13):1945–7.
7. Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, et al. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage. Biochem Biophys Res Commun. 2007;358(1):104–10.
8. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A. 2008;105(31):10907–12.
9. Maitta RW, Wolgast LR, Wang Q, Zhang H, Bhattacharyya P, Gong JZ, et al. Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. Am J Hematol. 2011;86(2):230–4.
10. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain. 2011;134(Pt 7), e178.
11. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett. 2000;287(1):65–7.
12. Foulds PG, Diggle P, Mitchell JD, Parker A, Hasegawa M, Masuda-Suzukake M, et al. A longitudinal study on alpha-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep. 2013;3:2540.
13. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70(10):1277–87.
14. Abd-Elhadi S, Honig A, Simhi-Haham D, Schechter M, Linetsky E, Ben-Hur T, et al. Total and proteinase K-resistant α-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson’s disease. Sci Rep. 2015;5:11120.
15. Goedert M. Neurodegeneration. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science. 2015;349(6248):1255555.
16. Lee HJ, Suk JE, Lee KW, Park SH, Blumbergs PC, Gai WP, et al. Transmission of synucleinopathies in the enteric nervous system of A53T alpha-synuclein transgenic mice. Exp Neurobiol. 2011;20(4):181–8.
17. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, et al. Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A. 2014;111(29):10732–7.
18. Greene JG. Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease. Antioxid Redox Signal. 2014;21(4):649–67.
19. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. 2015;522(7556):340–4.
20. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury Jr PT. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996;35(43):13709–15.
21. Beyer K, Ariza A. alpha-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol. 2013;47(2):509–24.
22. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron. 2003;37(4):583–95.
23. Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477(7362):107–10.
24. Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, et al. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A. 2011;108(43):17797–802.
25. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273(16):9443–9.
26. Martinez Z, Zhu M, Han S, Fink AL. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry. 2007;46(7):1868–77.
27. Bartels T, Kim NC, Luth ES, Selkoe DJ. N-Alpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLoS One. 2014;9(7), e103727.
28. Snead D, Eliezer D. Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol. 2014;23(4):292–313.
29. Zarbiv Y, Simhi-Haham D, Israeli E, Elhadi SA, Grigoletto J, Sharon R. Lysine residues at the first and second KTKEGV repeats mediate alpha-synuclein binding to membrane phospholipids. Neurobiol Dis. 2014;70:90–8.
30. DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20(11):1885–900.
31. Mollenhauer B. Quantification of alpha-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson's disease? Parkinsonism Relat Disord. 2014;20 Suppl 1:S76–9.
32. Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener. 2016;11(1):7.
33. Maroteaux L, Scheller RH. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res. 1991;11(3-4):335–43.
34. Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, et al. Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease. J Neurosci. 2014;34(6):2037–50.
35. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A. 2001;98(16):9110–5.
36. Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A, et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci. 2000;20(17):6365–73.
37. Ysselstein D, Joshi M, Mishra V, Griggs AM, Asiago JM, McCabe GP, et al. Effects of impaired membrane interactions on alpha-synuclein aggregation and neurotoxicity. Neurobiol Dis. 2015;79:150–63.
38. Burre J, Sharma M, Sudhof TC. alpha-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A. 2014;111(40):E4274–83.
39. Bodner CR, Maltsev AS, Dobson CM, Bax A. Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy. Biochemistry. 2010;49(5):862–71.
40. Sharma M, Burre J, Sudhof TC. CSPalpha promotes SNARE-complex assembly by chaperoning SNAP-25 during synaptic activity. Nat Cell Biol. 2011;13(1):30–9.
41. Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A. 2016;113(7):1931–6.
42. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R. Alpha-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic. 2009;10(2):218–34.
43. Vargas KJ, Makani S, Davis T, Westphal CH, Castillo PE, Chandra SS. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci. 2014;34(28):9364–76.
44. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006;313(5785):324–8.
45. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65(1):66–79.
46. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329(5999):1663–7.